ORCID "0000-0001-9636-4113" Bildiri Koleksiyonu için listeleme
-
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
Merih Urlu, Selin; Cengiz Seval, Güldane; Erdoğan Yücel, Elçin; Mehtap, Özgür; Yenihayat, Emel Merve; Polat, Merve Gökçen; Malkan, Ümit Yavuz; Karakuş, Volkan (American Society of Hematology, 2023)Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ... -
Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
Sevindik, Ömür Gökmen; Gemici, Aliihsan; Usta, Furkan Selim; Çakır, Aslı; Sadri, Sevil; Bekoz, Hüseyin; Sargın, Fatma Deniz (The American Society of Hematology, 2019)Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. ... -
Artificial intelligence to assist better myeloma care, is it the time?
Sevindik, Ömür Gökmen (Cıg Media Group, 2019)Myeloma treatment made an enormous progress during the last decade. Armamentarium is grossly enlarging each year in the field of treatment. Parallel to the progress achieved to provide better care for myeloma patients, ... -
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür Gökmen (American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Sevindik, Ömür Gökmen; Chen, Chang; Yang, Jing; Farooqui, Mohammed Z. H.; Paszkiewicz-Kozik, Ewa (Lippincott Williams & Wilkins, 2023)... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül (American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
Comparison of outcomes of total body irradiation (TBI) vs non-TBI conditioning regimens in acute lymphoblastic leukemia for allogeneic transplantation
Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Özçelik, Tülay; Arat, Mutlu; Hindilerden, İpek Yonal; Beşışık, Sevgi Kalayoğlu; Nalcacı, Meliha; Uzay, Ant; Kartı, Süleyman Sami; Kıvanç, Demet; Sargın, Deniz (Nature Publishing Group, 2019)... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
İlhan, Osman; Cengiz Seval, Güldane; Uzay, Ant; Kaya, Emin; Öztürk, Zübeyde Nur; Deveci, Burak; Yavaşoğlu, İrfan; Ural, Ali Uğur; Beköz, Hüseyin Saffet; Ayli, Meltem; Sevindik, Ömür Gökmen; Civriz Bozdağ, Sinem; Kurt Yüksel, Meltem; Gülbas, Zafer (Elsevier Science Inc, 2020)Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ... -
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
Pınar, İbrahim Ethem; Çelik, Serhat; Polat, Merve Gökçen; Karataş, Aylin Fatma; Doğan, Ali; Iltar, Utku; Cengiz Seval, Güldane; Sevindik, Ömür Gökmen (American Society of Hematology, 2023)Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ... -
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; İpek, Yıldız; Gedük, Ayfer; Harmandalı, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (CIG Media Group, 2021)Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ... -
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; Yıldız, İpek; Gedük, Ayfer; Harmandali, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kaşar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (American Society of Hematology, 2021)... -
Is the end close for the graft-versus-host disease that is a big problem following allogeneic hematopoetic stem cell transplantation?
İlhan, Osman; Cengiz Seval, Güldane; Özkurt, Zübeyde Nur; Ural, Ali Uğur; Aylı, Meltem; Sevindik, Ömür Gökmen; Civriz Bozdağ, Sinem; Kurt Yüksel, Meltem; Gülbaş, Zafer; Özcan, Muhit (American Society of Hematology, 2018)… -
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Lavie, David; Timmerman, John; Sanz, Ramon Garcia; Kim, Won Seog; Kim, Tae Min; Avigdor, Abraham; Dierickx, Daan; Jagadeesh, Deepa; Herrera, Alex Francisco (Lippincott Williams & Wilkins, 2023)... -
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
Lavie, David; Timmerman, John; Garcia-Sanz, Ramon; Kim, Won Seog; Kim, Tae Min; Avigdor, Abraham; Dierickx, Daan; Jagadeesh, Deepa; Molin, Daniel L.; Herrera, Alex F. (American Society of Hematology, 2023)Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ... -
Prospective real-world outcomes of acute myeloid leukemia
Karakuş, Volkan; Iltar, Utku; Yenihayat, Emel Merve; Polat, Merve Gökçen; Çelik, Serhat; Malkan, Ümit Yavuz; Cengiz Seval, Güldane; Alacacıoğlu, İnci (American Society of Hematology, 2023)Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ... -
Real-world data from the Turkish national chronic lymphocytic leukemia registry
Demirkan, Fatih; Sevindik, Ömür Gökmen (CIG Media Group, 2020)Objective: We have previously established a nationwide registry to obtain real-world data to document the demographics and treatment outcomes of Turkish CLL patients. Patients or other participants: Patients who were ... -
Retrospective analysis of Turkish AML registry database, on behalf of AML working group of Turkish society of hematology
Karakuş, Volkan; Sevindik, Ömür Gökmen; Karataş, Aylin; Yenihayat, Emel Merve; Polat, Merve Gökçen; Çelik, Serhat; Pınar, İbrahim Ethem; Alacacıoğlu, İnci (American Society of Hematology, 2022)Abstract Introduction: To investigate the demographics and treatment details of the acute myeloid leukemia (AML) patients who were diagnosed and followed up in Turkey. Methods: Patients who were recorded on the database ...